ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Targeting the innate immune system with nanoparticles for cancer immunotherapy

Li, Kai; Zhang, Zhicheng; Mei, Yu; Li, Mengmeng; Yang, Qingzhu; Wu, Qiong; Yang, Huanjie; He, Liangcan*; Liu, Shaoqin*哈尔滨医科大学
Journal of Materials Chemistry B2022-3-16DOI: 10.1039/d1tb02818a
11被引6阅读
引用收藏
分享

摘要

Various cancer therapies have advanced remarkably over the past decade. Unlike the direct therapeutic targeting of tumor cells, cancer immunotherapy is a new strategy that boosts the host's immune system to detect specific cancer cells for efficient elimination. Unfortunately, the efficacy of these treatments has been limited to a fraction of patients within a subset of tumor types, and further studies are still needed to clarify these mechanisms and develop novel approaches to improve the efficacy of cancer immunotherapy. Emerging data suggest that the innate immune system also plays a key role in tumor immunosurveillance and generation of antitumor immune responses. Nanoparticles incorporating immunomodulatory agents can activate immune cells and modulate the tumor microenvironment to enhance antitumor immunity. Such nanoparticle-based cancer immunotherapies have received considerable attention and have been extensively studied in recent years. In this review, we will discuss the anticancer activities of nanoparticles designed to target innate immune pathways, including Toll-like receptor, nucleotide-binding oligomerization domain-like receptor, and retinoic acid-inducible gene-I-like receptor pathways, as well as DNA sensing pathways. In addition, nanoparticles that target key innate immune cell types, such as macrophages, myeloid-derived suppressor cells, dendritic cells, natural killer cells, and neutrophils, also will be investigated. In summary, although further research and clinical studies are still needed to solve the safety concerns and improve the efficacy of nanoplatform-based cancer immunotherapy, the recent studies presented in this review prove that nanoparticle-incorporated cancer immunotherapy is a highly promising treatment for cancer patients.

学科与关键词

关键词
NATURAL-KILLER-CELLSMESOPOROUS SILICA NANOPARTICLESDENDRITIC CELLSTUMOR MICROENVIRONMENTSUPPRESSOR-CELLSENGINEERED NANOPARTICLESPLGA NANOPARTICLESANTITUMOR-ACTIVITYTRAINED IMMUNITYINTERFERING RNA
相关
加载中…

文献加载失败,请重试

重试

发表信息

论文状态
公开发表
期刊
Journal of Materials Chemistry B
发表日期
2022-03-16
卷期
第 10 卷, 第 11 期
页码
1709-1733
DOI
10.1039/d1tb02818a
语言
ENGLISH
期刊等级
2区
成果收录
SCIE
资助标注
National Science Fund for Distinguished Young Scholars [51825202]; National Natural Science Foundation of China [82172582, 81872439]; Natural Science Foundation of Heilongjiang Province [LH2020H072]

作者

  • L

    Li, Kai (第一作者)

    harbin inst technol

  • Z

    Zhang, Zhicheng

    harbin med univ

查看全部 9 位作者收起作者
  • M

    Mei, Yu

    harbin inst technol

  • L

    Li, Mengmeng

    harbin inst technol

  • Y

    Yang, Qingzhu

    qiqihar univ

  • W

    Wu, Qiong

    harbin inst technol

  • Y

    Yang, Huanjie

    harbin inst technol

  • H

    He, Liangcan (通讯)

    harbin inst technol

  • L

    Liu, Shaoqin (通讯)

    harbin inst technol

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417